U.S. regulatory status

Semaglutide (compounded)

Also known as Ozempic · Wegovy · compounded semaglutide

RestrictedEnforcement discretion ended; routine compounding no longer permitted

Is Semaglutide (compounded) legal right now?

Semaglutide is an FDA-approved drug (Ozempic, Wegovy), not a 503A bulk substance. Pharmacies were permitted to compound copies of it only while it sat on the FDA drug-shortage list. After the FDA declared the shortage resolved in February 2025, that permission wound down — ending April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities — and the FDA now treats mass compounding of "essentially a copy" of the approved drug as an actionable violation. A narrow exception survives for patient-specific products that are not essentially a copy. In April 2026 the FDA proposed to permanently exclude semaglutide from the 503B bulks list.

Restricted: Prescription-only, banned, controlled, or under active FDA enforcement.

Current status held since Apr 22, 2025 · last verified Jul 7, 2026 (ET)

Primary source: Federal Register All 4 sources

Where it sits in the process

Nominated(passed)
Under review(passed)
Rulemaking(stalled here — not advancing)
Compounding-legal(not reached)

Not on a path to the 503A list right now. The process stalled or reversed at this stage — read the status above. Sitting at an earlier step is not a sign it will advance.

Next milestoneComment period closes — FDA proposal to exclude semaglutide from the 503B bulks list — Jul 30, 2026 (in 22 days)

What changed last

Apr 30, 2026
FDA proposed to permanently exclude semaglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk. This is a proposal in a comment period, not a final change.
Review scheduledView source
May 22, 2025
503B enforcement discretion for compounding semaglutide ended (503A ended April 22, 2025), following the resolved shortage.
EnforcementView source

Status elsewhere

Semaglutide (compounded): regulatory status by jurisdiction
Jurisdiction	Status	Note
United States (FDA)	Restricted	Enforcement discretion ended Apr 22, 2025 (503A) / May 22, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow patient-specific 503A exception remains.
Australia (TGA)	Restricted	GLP-1 analogues removed from the pharmacist compounding exemption effective Oct 1, 2024; remains Schedule 4.
Sport / anti-doping (WADA)	Unscheduled	Not prohibited; on the WADA Monitoring Program since 2024.

Sources & transparency

Sources for this entry

Federal Register — 503B bulk drug substances clinical-need proposal (semaglutide) Federal Register · primaryFDA proposes not to include semaglutide on the 503B bulks list; underpins the restricted status.
McDermott — semaglutide shortage resolved; compounding wind-down analysis503A enforcement discretion ended Apr 22, 2025; 503B ended May 22, 2025; narrow exceptions only.
Alston & Bird — FDA resolves semaglutide shortage analysisContinued compounding only of products not 'essentially a copy' for individual patient needs.
EMJ — GLP-1 receptor agonists on WADA Monitoring Program analysisSemaglutide monitored, not prohibited.

Last verified by a human: Jul 7, 2026 (ET) · how we verify
Who runs this: Peptlas Research Team — independent. About us.
What we sell: Nothing. No products, no affiliates, no sponsored placements.

This page reports publicly available regulatory status for information only. It isnot medical or legal advice and makes no health claim. See ourfull disclaimer.